Korean J Gastroenterol.  2000 Jan;35(1):64-72.

Acute Exacerbation of Hepatitis in Hepatitis B Virus Carriers with Non-Hodgkin's Lymphoma after Chemotherapy

• Kwag JY
• Jung SH
• Kang YK
• Han CJ
• Kim YC
• Lee JO
• Ryoo BY
• Kim BS
• Hong HJ
• Lee YW
• Lee SW
• Cho JA
• Lee GH
• Kim CM

Abstract

BACKGROUND/AIMS
Immunosuppressive therapy such as anti-cancer chemotherapy is often complicated with reactivation of hepatitis B. We tried to investigate the prevalence of hepatitis B virus (HBV) infection in patients with non-Hodgkin's lymphoma (NHL). Furthermore, we evaluated the frequency of hepatic complications, the clinical outcome, and the risk factors associated with the development of hepatic complications in HBsAg-positive patients treated with chemotherapy for NHL. METHODS: One hundred eighty-five patients who were diagnosed as NHL and treated with chemotherapy were retrospectively analyzed.
RESULTS
The prevalence of HBV infection was 14.1% of the patients. The frequency of hepatic complications in HBsAg-positive patients receiving chemotherapy for NHL was significantly higher than those of HBsAg-negative patients. (50% vs. 10.1%), and the complete response (CR) rate was significantly lower (42.3% vs. 67.9%). We could not find any significant risk factor associated with the development of hepatic complications in HBsAg-positive NHL patients received chemotherapy. CONCLUSIONS: For HBsAg-positive NHL patients receiving chemotherapy, special concern and close follow-up is needed because of high frequency of hepatic complication and low CR rate caused by chemotherapy.

Keyword

Hepatitis B; Non-Hodgkin's lymphoma; Anti-cancer chemotherapy

MeSH Terms

Drug Therapy*
Follow-Up Studies
Hepatitis B virus*
Hepatitis B*
Hepatitis*
Humans
Lymphoma, Non-Hodgkin*
Prevalence
Retrospective Studies
Risk Factors